AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center's Ongoing Study in Cancer Patients with COVID-19
AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center's Ongoing Study in Cancer Patients with COVID-19
OCALA, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center (Roswell Park) has approved a protocol amendment to Roswell Park's ongoing Phase 1/2a study evaluating the two-drug combination of AIM's Ampligen and interferon alpha-2b as a potential early-onset treatment for patients with cancer and mild-to-moderate COVID-19.
The IRB-approved amendment calls for randomization of an additional twenty patients. Ten of these patients will receive a single dose of Ampligen, but no interferon treatment, and the other ten will receive best available care only. Ampligen alone has a generally well-tolerated safety profile with lower risk of adverse events than is generally expected with interferon therapy.
"We are excited to see Ampligen tested not only as part of an antiviral treatment combination for COVID-19 among cancer patients, but also as a possible standalone therapy for this terrible virus," said AIM CEO Thomas K. Equels. "An early-onset treatment is especially critical for cancer patients, who face significantly increased risk of severe symptoms or death."
https://aimimmuno.irpass.com/ViewEmail.asp?b=2265&id=200459&p=2190717&I=1243298-K2r3p5x9n5